Daiichi Sankyo to support Phase I clinical study of anticoagulant activity reverser for edoxaban

USA-based Perosphere and Japanese drug major Daiichi Sankyo(TYO: 4568) have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a Phase I clinical study testing the safety, tolerability and effectiveness of PER977 to reverse the anticoagulant activity of edoxaban, Daiichi Sankyo's investigational oral, once-daily, direct factor Xa-inhibitor.

PER977 is a synthetic, small new molecular entity being developed by Perosphere that has been shown in preclinical studies to directly bind to heparins as well as circulating direct factor Xa- and IIa-inhibitors and therefore has the potential to reverse their anticoagulant effect.

"Novel oral anticoagulants were developed to help address the limitations of older anticoagulant agents, such as the need for frequent dose adjustments and monitoring," said Jack Ansell, Professor of Medicine, at NYU School of Medicine, and an advisor to Perosphere. "However, during severe bleeding or the need for emergency intervention, there is no established therapy to reverse the anticoagulant activity of these agents," he added.